STERIS plc (STE) Form 8-K — Nov 4, 2026
STERIS plc reported fiscal 2027 second quarter revenue of $1.6 billion, up 9% as reported with 8% constant currency organic growth. Adjusted diluted EPS rose to $2.94 from $2.47 a year ago, with Life Sciences delivering standout 18% revenue growth and 53% capital equipment growth. The company raised its FY2027 adjusted EPS guidance to $11.35-$11.55 from $11.10-$11.30, reflecting stable underlying performance and roughly $0.18 of benefit from tariff refunds received year-to-date. STERIS also approved a new targeted restructuring plan, primarily in Healthcare, with total charges of approximately $45 million and expected annualized savings of about $9 million.
Key figures
- Eps
- 2.19
- Guidance
- FY2027 as-reported revenue growth 7-8%, constant currency organic growth 6-7%; adjusted EPS raised to $11.35-$11.55 from $11.10-$11.30 (includes ~$0.18 benefit from tariff refunds)
- Net Income
- 213700000
- Cash Position
- 531100000
- Shares Outstanding
- 97300000
- Ast revenue q2
- 295600000
- Adjusted eps q2
- 2.94
- Adjusted net income q2
- 286800000
- Life sciences revenue q2
- 170600000
- Free cash flow six months
- 492500000
- New restructuring charges
- ~$45 million total (~$25M in Q2)
- Tariff refund pretax benefit
- ~$20 million
- Fy2027 free cash flow outlook
- 800000000
- Operating cash flow six months
- 656100000
- Constant currency organic growth
- 8%
- Restructuring annualized savings
- ~$9 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.